Multiple immunomodulatory pathways

"Multiple immunomodulatory pathways" does not refer to a single molecular target but rather encompasses the diverse network of cellular signals and molecular interactions that regulate the immune response. These include both innate and adaptive immunity mechanisms—such as pattern recognition receptors (PRRs), cytokines, co-stimulatory/co-inhibitory molecules on T cells, metabolic regulators within mesenchymal stromal cells, among others—that collectively determine how the body responds to pathogens, tumors, autoantigens, and other stimuli. Therapeutic interventions may aim to enhance or suppress specific arms of these networks depending on disease context; examples include biologics targeting cytokines for autoimmune diseases or checkpoint inhibitors for cancer therapy. Because this term describes an entire class/set rather than an individual molecule/receptor/enzyme/transporter/etc., it is not considered a canonical therapeutic target itself but instead refers broadly to all targets involved in modulating immunity at multiple points along these complex biological routes.

Mechanisms vary widely depending on the pathway and drug: - Suppression of cytokine production or action (e.g., anti-TNF agents) - Modulation of T cell activation/inhibition via co-stimulatory or checkpoint molecules (e.g., PD1/PDL1 inhibitors) - Interference with intracellular signaling cascades such as JAK/STAT inhibition by JAK inhibitors